DALLAS and NEW YORK, Sept. 8 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer, supportive care, today announced that the Company will present at the Rodman & Renshaw Annual Healthcare Conference in New York City on Tuesday, September 14th at 9:35AM ET in the Fahnestock Salon, located on the 5th floor of the New York Palace Hotel.
On Tuesday, Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation on the Company's commercial launch of its lead product, MuGard, and detail the development strategy for ongoing programs within its drug pipeline. A live webcast of the presentation may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq18/accp. A replay of the presentation will be archived and may be accessed under the investor relations section of the company's website, www.accesspharma.com. Management will be available to meet with investors or licensing partners September 13-15. To arrange a one-on-one meeting with Access management at the conference, please email Christine Berni, email@example.com.
MuGard is an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. Access' commercial launch of MuGard in North America is underway. Access recently announced its MuGard Centers-of-Excellence Sampling program with leading oncology networks and a specialty distribution agreement with BioScrip (BIOS). Rolling launches for MuGard in the UK, Germany, Italy, Sweden, Norway and Greece, have been conducted through its European partner, SpePharm. Additionally, JCOM, Inc., its Korean licensee for MuGard has received approval from the Korean Food and Drug Administration (KFDA) and Access signed an agreement with RHEI Pharmaceuticals, to market MuGard in China and Certain Other Southeast Asian Countries.
For more information about the Rodman & Renshaw 12th Annual Global Healthcare Conference, go to: http://www.rodm.com/conferences?id=51.
About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: CompanyContact: Investor RelationsChristine BerniDonald C. Weinberger/Diana Bittner (media)Director of Investor RelationsWolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.(212) 370-4500(212) 786-6208
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved